Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  UCB    UCB   BE0003739530

UCB

(UCB)
  Report
Real-time Quote. Real-time Tradegate - 01/27 08:54:52 am
80.85 EUR   -1.64%
01/21UCB : Transparency notification UCB SA/NV
PU
01/20UCB : Share buyback
CO
01/20UCB : Threshold crossings
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

UCB : S.A - Transparency notifications BlackRock, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/11/2019 | 08:15am EST

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 5 and 6 November 2019 respectively.

In the first notification, BlackRock, Inc., has notified that, following a disposal of UCB shares with voting rights by its affiliates, its holding of UCB shares with voting rights has decreased and has crossed downwards the 5% threshold on 4 November 2019.

On 4 November 2019, BlackRock, Inc. (taking into account the holding of its affiliates) Inc. owned 9 677 390 UCB shares with voting rights (versus 9 841 224 in its previous notification), representing 4.98% of the total number of shares issued by the company (194 505 658) (versus 5.06% in its previous notification), as well as 225 581 equivalent financial instruments (versus 481 019 in its previous notification) representing 0.12% of the total number of shares issued by the company (versus 0.25% in its previous notification).

In the second notification, BlackRock, Inc., has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its holding of UCB shares with voting rights has increased and has crossed the 5% threshold on 5 November 2019.

On 5 November 2019, BlackRock, Inc. (taking into account the holding of its affiliates) 9 753 879 UCB shares with voting rights, representing 5.01% of the total number of shares issued by the company, as well as 216 713 equivalent financial instruments, representing 0.11% of the total number of shares issued by the company.

Contact:

Antje Witte

Tel: +32.2.559.94.14

Email: antje.witte@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of EUR 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB).

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
BLACKROCK, INC. -0.94% 536.84 Delayed Quote.6.79%
UCB -1.58% 80.94 Delayed Quote.15.94%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on UCB
01/21UCB : Transparency notification UCB SA/NV
PU
01/20UCB : Share buyback
CO
01/20UCB : Threshold crossings
CO
01/14UCB : S.A - Transparency notification BlackRock, Inc
AQ
01/14UCB : S.A. - Disposal of own shares
AQ
01/13UCB : Transparency notification BlackRock, Inc.
PU
01/13UCB : Disposal of own shares
PU
01/13UCB : Threshold crossings
CO
01/10UCB : Belgium's UCB raises 2019 forecasts after net sales beat in fourth quarter
RE
01/10UCB : updates its financial outlook for 2019
PU
More news
Financials (EUR)
Sales 2019 4 795 M
EBIT 2019 1 113 M
Net income 2019 779 M
Finance 2019 395 M
Yield 2019 1,42%
P/E ratio 2019 19,9x
P/E ratio 2020 19,7x
EV / Sales2019 3,15x
EV / Sales2020 3,13x
Capitalization 15 484 M
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 86,76  €
Last Close Price 82,20  €
Spread / Highest target 25,3%
Spread / Average Target 5,55%
Spread / Lowest Target -13,6%
EPS Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Evelyn du Monceau Chairman
Charl van Zyl Chief Operating Officer
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
UCB15.94%17 073
CSL LIMITED12.67%96 254
BIOGEN INC.-6.27%50 188
SAMSUNG BIOLOGICS CO LTD--.--%27 336
ALEXION PHARMACEUTICALS-2.67%23 295
GRIFOLS-0.86%20 673